Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 28, 2018

View Archived Issues

CBT and Zhejiang Bossan announce collaborate to develop combination cancer treatments

Simple sugar may impair cancer growth in mice

Alunbrig approved in Europe for patients with ALK+ NSCLC previously treated with crizotinib

Melinta Therapeutics granted marketing authorization for Vabomere in Europe

Athenex initiates phase I/II trial of Oraxol in combination with pembrolizumab

First patient dosed in phase II study of omadacycline in acute pyelonephritis

Evelo Biosciences announces plans for first monoclonal microbial oncology product candidate

Phase III CheckMate-451 study of Opdivo with Yervoy in extensive-stage SCLC misses primary endpoint

Acquist Therapeutics presents data for novel dual XO and URAT1 inhibitor RLBN-1127

Glenmark Pharmaceuticals discovers NADPH oxidase inhibitors

Wockhardt describes new antibacterial diazabicyclooctane derivatives

University of California, Oakland, Istituto Italiano di Tecnologia (IIT) patent RhoJ inhibitors

Moderna Therapeutics begins phase I study of mRNA-2752 in advanced malignancies

University of Louisville describes anticancer copper complexes

ViiV Healthcare presents HIV replication inhibitors

ER-INP as novel therapeutic strategy for drug-induced acute liver injury

ET-D5 demonstrates promising in vivo efficacy as potential new anticancer therapy

First-in-human data for MK-4280 alone or in combination with pembrolizumab

FDA clears IND for PBCAR-0191 allogeneic CAR T product candidate

Vertex reports phase III data on VX-659 triple combination regimen for cystic fibrosis

New phase I trial explores nasal administration of foralumab in healthy volunteers

Bile acid receptor implicated in hepatic encephalopathy due to liver cirrhosis

Spark Therapeutics to begin phase I/II study of SPK-8016 gene therapy in hemophilia A

Preclinical evaluation of zifaxaban, an oral inhibitor of factor Xa for thromboembolic diseases

New deep vein thrombosis model allows real-time in vivo imaging

Preclinical results of EAGLE technology targeting glyco-immune checkpoints for cancer treatment

Phase II trial of bemcentinib/pembrolizumab combination in patients with advanced NSCLC and melanoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...